This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ren, S.-G. Articles by Melmed, S. Search for Related Content PubMed PubMed Citation Articles by Ren, S.-G. Articles by Melmed, S.

Functional Association of Somatostatin Receptor Subtypes 2 and 5 in Inhibiting Human Growth Hormone Secretion

Cedars-Sinai Research Institute (S.-G.R., R.Y., S.M.), University of California, Los Angeles, School of Medicine, Los Angeles, California 90048; and Biomeasure Inc. (J.T., J.D., M.D.C.), Milford, Massachusetts 01757

Address all correspondence and requests for reprints to: Shlomo Melmed, M.D., Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048. E-mail: melmed{at}cshs.org.

We previously demonstrated that somatostatin (SRIF)-induced inhibition of GH secretion from human pituitary cells is mediated through both the SRIF receptor (SSTR) 2 and 5 subtypes. The interplay between these two SSTR subtypes in regulating GH was therefore tested in primary human fetal pituitary cultures (18–30 wk gestation). GHRH (10 nM)-stimulated GH secretion (51% increase, P < 0.05) was suppressed equally by either SSTR2 or SSTR5-selective agonists (10 nM). GH suppression correlated with agonist affinity for their respective receptor subtypes. Combined addition of SSTR2- and SSTR5-specific agonists was synergistic for GH suppression, achieving 73% (P < 0.05) inhibition as compared with inhibition attained with SSTR2 (32%) and SSTR5 (34%) agonists used alone (P < 0.05). The SSTR2 selective antagonist BIM-23454 dose-dependently blocked SSTR2 but not SSTR5-induced suppression of GH secretion. BIM-23454 also completely reversed GH suppression in response to the combined activation of SSTR2 and SSTR5. The IC₅₀ for BIM-23454 reversal of agonist-induced GH suppression was 55 nM and 33 nM for two SSTR2 agonists, 45 nM and 40 nM for the combination of SSTR2 and SSTR5 agonists, respectively, and 45 nM for the SSTR2/SSTR5 agonist BIM-23244, all of which were similar to the affinity of BIM-23454 for SSTR2 (32 nM). These results suggest the following: 1) activation of both SSTR2 and SSTR5 induces a functional association of receptor subtypes, resulting in synergistic GH suppression; 2) BIM-23454 is a potent SSTR2-selective antagonist capable of reversing SRIF-induced GH suppression; and 3) the ability of a selective SSTR2 antagonist to inhibit the GH suppressing action of SSTR2 agonist alone, SSTR2/SSTR5 biselective agonists, or SSTR2 and SSTR5 agonists in combination support the concept of a functional interaction between somatotroph SSTR2 and SSTR5 subtypes in primary human fetal pituitary cells.

This work was supported by grants from Biomeasure Inc., the Doris Factor Molecular Endocrinology Laboratory, and the Annenberg Foundation.

Abbreviations: CHO, Chinese hamster ovary; Ki, affinity constant; PRL, prolactin; SRIF, somatostatin; SSTR, SRIF receptor.

This article has been cited by other articles:

				E. Peverelli, A. G. Lania, G. Mantovani, P. Beck-Peccoz, and A. Spada Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop Endocrinology, July 1, 2009; 150(7): 3169 - 3176. [Abstract] [Full Text] [PDF]

				M. van Hoek, L. J. Hofland, Y. B. de Rijke, F. H. van Nederveen, R. R. de Krijger, P. M. van Koetsveld, S. W. J. Lamberts, A. J. van der Lely, W. W. de Herder, and R. A. Feelders Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid, in Vivo and in Vitro Studies J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 428 - 433. [Abstract] [Full Text] [PDF]

				M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]

				F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2 Endocrinology, September 1, 2008; 149(9): 4736 - 4746. [Abstract] [Full Text] [PDF]

				U. Plockinger, S. Albrecht, C. Mawrin, W. Saeger, M. Buchfelder, S. Petersenn, and S. Schulz Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1203 - 1210. [Abstract] [Full Text] [PDF]

				N. Kimura, N. Takamatsu, Y. Yaoita, R Y. Osamura, and N. Kimura Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation J. Mol. Endocrinol., February 1, 2008; 40(2): 75 - 91. [Abstract] [Full Text] [PDF]

				E. Resmini, P. Dadati, J.-L. Ravetti, G. Zona, R. Spaziante, A. Saveanu, P. Jaquet, M. D. Culler, F. Bianchi, A. Rebora, et al. Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1592 - 1599. [Abstract] [Full Text] [PDF]

				N. Sharif, L. Gendron, J. Wowchuk, P. Sarret, J. Mazella, A. Beaudet, and T. Stroh Coexpression of Somatostatin Receptor Subtype 5 Affects Internalization and Trafficking of Somatostatin Receptor Subtype 2 Endocrinology, May 1, 2007; 148(5): 2095 - 2105. [Abstract] [Full Text] [PDF]

				G. Tulipano and S. Schulz Novel insights in somatostatin receptor physiology Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S3 - S11. [Abstract] [Full Text] [PDF]

				J. van der Hoek, S. W J Lamberts, and L. J Hofland Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S45 - S51. [Abstract] [Full Text] [PDF]

				G. F Taboada, R. M Luque, W. Bastos, R. F C Guimaraes, J. B Marcondes, L. M C Chimelli, R. Fontes, P. J P Mata, P. N. Filho, D. P Carvalho, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas Eur. J. Endocrinol., January 1, 2007; 156(1): 65 - 74. [Abstract] [Full Text] [PDF]

				M. Duran-Prado, C. Bucharles, B. J. Gonzalez, R. Vazquez-Martinez, A. J. Martinez-Fuentes, S. Garcia-Navarro, S. J. Rhodes, H. Vaudry, M. M. Malagon, and J. P. Castano Porcine Somatostatin Receptor 2 Displays Typical Pharmacological sst2 Features but Unique Dynamics of Homodimerization and Internalization Endocrinology, January 1, 2007; 148(1): 411 - 421. [Abstract] [Full Text] [PDF]

				E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer, September 1, 2006; 13(3): 955 - 962. [Abstract] [Full Text] [PDF]

				H. Rubinfeld, M. Hadani, G. Barkai, J. E. Taylor, M. D. Culler, and I. Shimon Cortistatin Inhibits Growth Hormone Release from Human Fetal and Adenoma Pituitary Cells and Prolactin Secretion from Cultured Prolactinomas J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2257 - 2263. [Abstract] [Full Text] [PDF]

				R. M. Luque, M. Duran-Prado, S. Garcia-Navarro, F. Gracia-Navarro, R. D. Kineman, M. M. Malagon, and J. P. Castano Identification of the Somatostatin Receptor Subtypes (sst) Mediating the Divergent, Stimulatory/Inhibitory Actions of Somatostatin on Growth Hormone Secretion Endocrinology, June 1, 2006; 147(6): 2902 - 2908. [Abstract] [Full Text] [PDF]

				P Jaquet, G Gunz, A Saveanu, H Dufour, J Taylor, J Dong, S Kim, J-P Moreau, A Enjalbert, and M D Culler Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy Eur. J. Endocrinol., July 1, 2005; 153(1): 135 - 141. [Abstract] [Full Text] [PDF]

				A. Ben-Shlomo, K. A. Wawrowsky, I. Proekt, N. M. Wolkenfeld, S.-G. Ren, J. Taylor, M. D. Culler, and S. Melmed Somatostatin Receptor Type 5 Modulates Somatostatin Receptor Type 2 Regulation of Adrenocorticotropin Secretion J. Biol. Chem., June 24, 2005; 280(25): 24011 - 24021. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, D. Piccin, A. Bottoni, M. R. Ambrosio, A. Margutti, R. Padovani, M. Scanarini, J. E. Taylor, M. D. Culler, L. Cavazzini, et al. Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on {alpha}-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomas in Vitro J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5181 - 5188. [Abstract] [Full Text] [PDF]

				R. D. Murray, K. Kim, S.-G. Ren, I. Lewis, G. Weckbecker, C. Bruns, and S. Melmed The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3027 - 3032. [Abstract] [Full Text] [PDF]

				L. J. Hofland, J. van der Hoek, P. M. van Koetsveld, W. W. de Herder, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, R. Feelders, A.-J. van der Lely, et al. The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1577 - 1585. [Abstract] [Full Text] [PDF]

				S.-G. Ren, S. Kim, J. Taylor, J. Dong, J.-P. Moreau, M. D. Culler, and S. Melmed Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5414 - 5421. [Abstract] [Full Text] [PDF]